CARLSBAD, Calif., Nov. 23 /PRNewswire/ -- Medex, Inc. has announced a major syringe pump conversion with Children’s Hospital Boston (Massachusetts), an opportunity with revenue potential of over $2 million for Medex. Under this contract, Medfusion(TM) 3500 Syringe Pumps with PharmGuard(TM) Medication Safety Software, the most recent innovation in Medex infusion technology, have been delivered and implemented house-wide at Children’s Hospital.
Medex infusion systems are a market leader in areas including Neonatal and Pediatric intensive care units. According to Al Patterson, Director of Pharmacy, “The 3500 will improve our ability to safely administer meds and will provide a pathway to tie syringe pump administration to our clinical information system, further enhancing patient safety.”
Dominick Arena, President/CEO of Medex, stated, “This contract puts leading-edge technologies in the hands of the caregiver, tools used in the treatment of the smallest patients. We are proud to be able to provide this system to support clinician efforts in treating their at-risk patients.”
The Medfusion(TM) 3500 Syringe Pump features PharmGuard(TM) Medication Safety Software, designed to reduce medication delivery errors by encouraging programmable upper and lower dose limits. When exceeded, these safety limits alert the clinician and provide an electronic record of the event. FlowSentry(TM), a comprehensive array of pressure-related safety features (including rapid occlusion response time and pressure trend displays) is fully integrated. The Medfusion(TM) 3500 also includes a robust informatics platform, importing and exporting data as an integrated part of any patient data management system using a variety of adaptive protocols.
“This becomes a wonderful opportunity to demonstrate our safety technology platform -- an intuitive system designed to enhance safety while maintaining simplicity. Customer benefits include streamlined implementation, improved workflow and overall value,” continued Arena. “This was truly a team effort, with our account team working side-by-side with the customer to determine the best solution. When we sell leading-edge technology, everyone wins -- Medex, our customers and their patients.”
Children’s Hospital Boston is home to the world’s largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults for over 100 years. Founded in 1869 as a 20-bed hospital for children, Children’s Hospital Boston today is a 300-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children’s also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital visit http://www.childrenshospital.org/.
About Medex
Medex is a global manufacturer and marketer of critical care and alternate care medical products used in both acute and alternate care settings for a variety of therapeutic, diagnostic and long-term procedures. Medex markets and sells critical care systems and products to over 5,500 hospitals, health care systems, and alternate healthcare settings in more than 75 countries through a global sales force and distribution network. Headquartered in Carlsbad, California, the Company employs approximately 2,000 people worldwide. For more information please visit http://www.medex.com/.
Forward-Looking Statements
This news release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. Detailed information about such risk factors is set forth in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update, alter or release publicly any revisions to its forward-looking statements, whether as a result of new information, subsequent events or developments.
Contact: Gregory Aranaga Director, Corporate Communications +1 (760) 602 4455 garanaga@medex.comhttp://www.medex.com/
Medex, Inc.
CONTACT: Gregory Aranaga, Director, Corporate Communications of Medex,Inc., +1-760-602-4455, garanaga@medex.com
Web site: http://www.childrenshospital.org/
Web site: http://www.medex.com/